Morten A. Kall
Research Subjects
Research Interests
Morten A. Kall has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Eric Woolf
Department of Drug Metabolism, Merck Research Laboratory, West Point, PA 19438, USA
1 shared publicationIrong Fu
Department of Drug Metabolism, Merck Research Laboratory, West Point, PA 19438, USA
1 shared publicationMartin Jørgensen
Department of Early Development Pharmacokinetics, Drug Development ADME, H. Lundbeck, A/S Ottiliavej 7-9, DK-2500 Valby-Copenhagen, Denmark
1 shared publicationMartin J⊘Rgensen
Department of Bioanalysis, Drug ADME Research, H. Lundbeck A/S Ottiliavej 7–9, DK-2500Valby-Copenhagen, Denmark
1 shared publicationMorten Rohde
Department of Bioanalysis, Drug ADME Research, H. Lundbeck A/S Ottiliavej 7-9, DK-2500 Valby-Copenhagen, Denmark
1 shared publicationPatrick Vallano
Department of Drug Metabolism, Merck Research Laboratory, West Point, PA 19438, USA
1 shared publication
Latest Publications
- 16 November 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (22) , 2881-2894
Quantitative Determination of The Antidepressant Vortioxetine and its Major Human Metabolite in Plasma
Background: Vortioxetine is a novel antidepressant that has been developed in a joint partnership between H. Lundbeck A/S and the Takeda Pharmaceutical Company, Ltd. Results: A number of bioanalytical methods have been developed in order to support the nonclinical and clinical development of the drug. Method performance, long-term stability, urine analysis, unspecific binding and metabolites analysis are presented and discussed. Conclusion: Two different method applications for the quantification of vortioxetine and its major human metabolite in human plasma, an isocratic cation exchange HPLC–MS/MS method utilizing C8-SPE sample extracts and a reversed-phase UPLC–MS/MS method with gradient elution of protein precipitated sample extracts, have been validated according to current regulatory standards and applied in support to a large number of nonclinical as well as clinical studies.
- 16 November 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (22) , 2881-2894
Quantitative Determination of The Antidepressant Vortioxetine and its Major Human Metabolite in Plasma
Background: Vortioxetine is a novel antidepressant that has been developed in a joint partnership between H. Lundbeck A/S and the Takeda Pharmaceutical Company, Ltd. Results: A number of bioanalytical methods have been developed in order to support the nonclinical and clinical development of the drug. Method performance, long-term stability, urine analysis, unspecific binding and metabolites analysis are presented and discussed. Conclusion: Two different method applications for the quantification of vortioxetine and its major human metabolite in human plasma, an isocratic cation exchange HPLC–MS/MS method utilizing C8-SPE sample extracts and a reversed-phase UPLC–MS/MS method with gradient elution of protein precipitated sample extracts, have been validated according to current regulatory standards and applied in support to a large number of nonclinical as well as clinical studies.
- 15 October 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 858 (1-2) , 168-176
Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection
- 15 October 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 858 (1-2) , 168-176
Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection